Clinical Analysis of 37 Patients with Primary Tonsil Diffuse Large B Cell Lymphoma.
10.19746/j.cnki.issn.1009-2137.2019.02.019
- Author:
Tian TIAN
1
;
Li WANG
1
;
Hua-Yuan ZHU
1
;
Jin-Hua LIANG
1
;
Wei WU
1
;
Lei CAO
1
;
Lei FAN
1
;
Jian-Yong LI
1
;
Wei XU
2
Author Information
1. Department of Hematology, The First Affiliated Hospital of Nanjing Medical University (Jiangsu Province People＇s Hospital) , Nanjing 210029, Jiangsu province, China.
2. Department of Hematology, The First Affiliated Hospital of Nanjing Medical University (Jiangsu Province People＇s Hospital) , Nanjing 210029, Jiangsu province, China,E-mail: xuwei0484@jsph.org.cn.
- Publication Type:Journal Article
- MeSH:
Aged;
Humans;
Lymphoma, Large B-Cell, Diffuse;
Middle Aged;
Palatine Tonsil;
Prognosis;
Tonsillar Neoplasms
- From:
Journal of Experimental Hematology
2019;27(2):426-432
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the clinical manifestation, immunophenotypes and prognostic factors of patients with primary tonsil afftive large B cell lymphoma ( PT-DLBCL ).
METHODS:The clinical data including clinical characterstics, typing, staging, treatment efficacy and prognostic factors of PT-DLBCL patients were collected and analyzed restrospectively.
RESULTS:Out of 36 cases with the detinite cell origin, 24 cases (66.7%) were detecmined as the type of germinal center B-cell (GCB) and 12 cases (33.3%) was non-germinal center B-cell (non-GCB), 15 (40.5%) out of 37 cases were in Ann Arbor stage Ⅰ, and 22 (59.5%) in stage Ⅱ. With the median follow-up of 44 (10-101) months, 2 cases (5.4%) failed to be followed-up, after treatment for 6 (3-8) cycles 35 patients were evaluated. Among them 26 cases (74.3%) reached to complete remission (CR), 8 cases (22.9%) to partial remission ( PR ), and 1 (2.8%) to stable disease (SD). Both the 3 years and 5 years progression-free survival ( PFS ) were 82.5%, and both 3 and 5 years overall survival (OS) were 95.5%. 5 cases (13.5%) received radiotherapy. The patients aged＞60 ( P＜0.05 ) or aged＞70 (P＜0.05) had shorter PFS than younger patients. The patients with increased lactic dehydrogenase ( LDH ) level (P＜0.01) and without rituximab (R) (P＜0.05) in the treatment regimen had relatively short OS.
CONCLUSION:The patients sensitive to chemotherapy and/or radiotherapy have a good prognosis. Most of the patients can obtain long-term survival after treatment. The effect of combined immunotherapy are better than that of the simple chemotherapy.
